Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIGHT 2 clinical trial of fezolinetant for the treatment

09/23/2021 | 08:05am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') will present 12-week results (S-13) from the pivotal Phase 3 SKYLIGHT 2 clinical trial of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause on Friday, September 24, 2021 during the Top-Scoring Abstract Presentations at The North American Menopause Society 2021 Annual Meeting in Washington, D.C. VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause.1

Findings showed fezolinetant 30 and 45 mg administered once-daily met the co-primary endpoints of the study, demonstrating a statistically significant reduction from baseline in the frequency and severity of moderate to severe VMS at weeks 4 and 12 versus placebo. Results also showed that improvement in VMS frequency and severity greater than placebo was observed through the 12-week placebo-controlled period, with improvement observed as early as one week after treatment onset for both doses.

Fezolinetant is an investigational, non-hormonal selective neurokinin-3 receptor (NK3R) antagonist that blocks a specific receptor in the temperature control center of the brain (the hypothalamus) to reduce the frequency and severity of VMS associated with menopause.2,3,4,5

'VMS are the most common menopausal symptoms for which women seek treatment, yet there have been limited non-hormonal options available to women and healthcare providers,' said Dr. Nanette Santoro, M.D., Professor and Chair, University of Colorado School of Medicine. 'These results from the SKYLIGHT 2 study show that fezolinetant has the potential to help reduce frequency and severity of moderate to severe VMS.'

For the co-primary endpoint of reduction in mean frequency of moderate to severe VMS versus placebo, fezolinetant 30 mg demonstrated a -1.82 (p=

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
More news
Financials
Sales 2022 1 327 B 11 688 M 11 688 M
Net income 2022 196 B 1 723 M 1 723 M
Net cash 2022 584 B 5 142 M 5 142 M
P/E ratio 2022 18,4x
Yield 2022 2,55%
Capitalization 3 627 B 31 899 M 31 957 M
EV / Sales 2022 2,29x
EV / Sales 2023 2,05x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 957,50 JPY
Average target price 2 486,15 JPY
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.22.80%31 899
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979